InspireMD (NYSE:NSPR) Insider Sells $17,753.23 in Stock

InspireMD, Inc. (NYSE:NSPR) insider Shane Thomas Gleason sold 7,073 shares of the company’s stock in a transaction that occurred on Monday, February 3rd. The shares were sold at an average price of $2.51, for a total transaction of $17,753.23. Following the transaction, the insider owned 1,109,733 shares in the company, valued at $2,785,429.83. The trade was a 0.63% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Shane Thomas Gleason also recently made the following trade(s):

• On Tuesday, May 19th, Shane Thomas Gleason sold 22,778 shares of InspireMD stock. The shares were sold at an average price of $1.01, for a total transaction of $23,005.78.

InspireMD Trading Down 2.9%

Shares of InspireMD stock opened at $1.00 on Friday. InspireMD, Inc. has a 12-month low of $0.97 and a 12-month high of $2.93. The firm has a market capitalization of $46.84 million, a price-to-earnings ratio of -1.33 and a beta of 0.82. The firm’s 50 day simple moving average is $1.38 and its two-hundred day simple moving average is $1.66.

Institutional Trading of InspireMD

Hedge funds have recently added to or reduced their stakes in the company. XTX Topco Ltd purchased a new stake in InspireMD during the fourth quarter worth $30,000. Renaissance Technologies LLC purchased a new stake in InspireMD during the first quarter worth $29,000. Virtu Financial LLC purchased a new stake in InspireMD during the fourth quarter worth $31,000. Creative Planning purchased a new stake in InspireMD during the second quarter worth $44,000. Finally, Uniting Wealth Partners LLC purchased a new stake in InspireMD during the third quarter worth $51,000. 44.78% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research analysts have issued reports on NSPR shares. Maxim Group started coverage on shares of InspireMD in a research note on Monday, February 2nd. They set a “buy” rating and a $6.00 price target on the stock. Lake Street Capital set a $4.00 price target on shares of InspireMD in a research note on Monday, May 4th. Piper Sandler restated an “overweight” rating and set a $3.00 price target (down from $4.00) on shares of InspireMD in a research note on Tuesday, May 5th. Finally, Loop Capital set a $5.00 price objective on shares of InspireMD in a report on Tuesday, February 24th. Three analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, InspireMD presently has a consensus rating of “Buy” and an average price target of $4.50.

More InspireMD News

Here are the key news stories impacting InspireMD this week:

• Positive Sentiment: Wall Street still has a constructive view on InspireMD, with multiple analysts maintaining Buy ratings and a consensus price target well above the current share price. InspireMD (NSPR) Stock Forecast & Price Target
• Neutral Sentiment: The latest insider sale by Shane Thomas Gleason involved 3,858 shares and was disclosed as being related to tax withholding obligations from vested equity awards, which often makes the transaction less meaningful as a trading signal. SEC filing
• Neutral Sentiment: There were several earlier insider sales by the same executive this month and in prior months, but the reported amounts were relatively small and also tied to equity-award tax obligations. SEC filing
• Negative Sentiment: Multiple insider sales can still pressure sentiment because investors may interpret them as limited near-term confidence, especially with NSPR trading near its 52-week low and below key moving averages. SEC filing

InspireMD Company Profile

InspireMD, Inc is a medical device company focused on developing next-generation stent technologies for cardiovascular and neurovascular interventions. The company’s core innovation lies in its MicroNet® mesh platform, a proprietary nanostructured covering designed to prevent embolic events during stent implantation. By integrating this fine mesh into traditional stent architectures, InspireMD aims to enhance safety and efficacy in the treatment of carotid artery disease and other vascular pathologies.

The company’s flagship offering, the CGuard® Embolic Prevention System (EPS), has received CE Mark approval and is commercially available in multiple international markets.